Responses to crizotinib in a patient with c-ros oncogene 1, receptor tyrosine kinase-positive advanced lung adenocarcinoma: A case report

Rearrangements to the c-ros oncogene 1, receptor tyrosine kinase (ROS1) gene are reported in 1–2% of lung adenocarcinomas. These rearrangements are associated with a response to the small-molecule tyrosine kinase inhibitor crizotinib. ROS1 rearrangements can be detected using fluorescence in situ hy...

Descripción completa

Detalles Bibliográficos
Autores principales: ZHANG, NA, YANG, JIN-JI, ZHANG, XU-CHAO, XIE, ZHI, WANG, BIN-CHAO, TU, HAI-YAN, JIANG, BEN-YUAN, WU, YI-LONG
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2014
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4214434/
https://www.ncbi.nlm.nih.gov/pubmed/25364439
http://dx.doi.org/10.3892/ol.2014.2571

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4214434/
https://www.ncbi.nlm.nih.gov/pubmed/25364439
http://dx.doi.org/10.3892/ol.2014.2571

Ejemplares similares